Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response

Infection and Immunity

Volumn 83, Issue 2, 2015, Pages 646-660

  Stanisic, Danielle I ^a,b,c   Fowkes, Freya J I ^a,b   Koinari, Melanie ^b   Javati, Sarah ^b   Lin, Enmoore ^b   Kiniboro, Benson ^b   Richards, Jack S ^a,d   Robinson, Leanne J ^a,b   Schofield, Louis ^a   Kazura, James W ^e   King, Christopher L ^e   Zimmerman, Peter ^e   Felger, Ingrid ^f,g   Siba, Peter M ^b   Mueller, Ivo ^a,b,h   Beeson, James G ^d,i  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^c GRIFFITH UNIVERSITY   (Australia)

^d BURNET INSTITUTE   (Australia)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^g UNIVERSITY OF BASEL   (Switzerland)

^h CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

ⁱ MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HOST FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M ANTIBODY; IMMUNOGLOBULIN M; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

AGE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPOSURE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNITY; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MEROZOITE; PAPUA NEW GUINEA; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; BLOOD; CLASSIFICATION; FEMALE; IMMUNOLOGY; INFANT; MALE; MICROBIOLOGY; PRESCHOOL CHILD; TRANSMISSION;

AGE FACTORS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; MALARIA, FALCIPARUM; MALE; MEROZOITES; PAPUA NEW GUINEA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84921324727     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02398-14     Document Type: Article

References (65)

1. Schofield L, Mueller I. 2006. Clinical immunity to malaria. Curr Mol Med 6:205-221. http://dx.doi.org/10.2174/156652406776055221.
2. Beeson J, Osier F, Engwerda C. 2008. Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol 24:578-584. http://dx.doi.org/10.1016/j.pt.2008.08.008.
3. Richards JS, Beeson JG. 2009. The future for blood-stage vaccines against malaria. Immunol Cell Biol 87:377-390. http://dx.doi.org/10.1038/icb.2009.27.
4. Cohen S, McGregor I, Carrington S. 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192:733-737. http://dx.doi.org/10.1038/192733a0.
5. McGregor IA, Carrington SP, Cohen S. 1963. Treatment of East African P. falciparum malaria with West African human -globulin. Trans R Soc Trop Med Hyg 57:170-175. http://dx.doi.org/10.1016/0035-9203(63)90058-0.
6. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P. 1991. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45:297-308.
7. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. 1990. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172:1633-1641. http://dx.doi.org/10.1084/jem.172.6.1633.
8. Cohen S, Butcher G, Crandall R. 1969. Action of malarial antibody in vitro. Nature 223:368-371. http://dx.doi.org/10.1038/223368a0.
9. Egan A, Burghaus P, Druilhe P, Holder A, Riley E. 1999. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol 21: 133-139. http://dx.doi.org/10.1046/j.1365-3024.1999.00209.x.
10. Khusmith S, Druilhe P, Gentilini M. 1982. Enhanced Plasmodium falciparum merozoite phagocytosis by monocytes from immune individuals. Infect Immun 35:874-879.
11. McCallum F, Persson K, Mugyenyi C, Fowkes F, Simpson J, Richards J, Williams T, Marsh K, Beeson J. 2008. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One 3:e3571. http://dx.doi.org/10.1371/journal.pone.0003571.
12. Persson K, McCallum F, Reiling L, Lister N, Stubbs J, Cowman A, Marsh K, Beeson J. 2008. Variation in use of erythrocyte pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Investig 118:342-351. http://dx.doi.org/10.1172/JCI32138.
13. Joos C, Marrama L, Polson HE, Corre S, Diatta AM, Diouf B, Trape JF, Tall A, Longacre S, Perraut R. 2010. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One 5:e9871. http://dx.doi.org/10.1371/journal.pone.0009871.
14. Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, McCallum FJ, Reiling L, Jaworowski A, Anders RF, Marsh K, Beeson JG. 2014. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med 12:108. http://dx.doi.org/10.1186/1741-7015-12-108.
15. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. 2010. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med 7:e1000218. http://dx.doi.org/10.1371/journal.pmed.1000218.
16. Braga E, Barros R, Reis T, Fontes C, Morais C, Martins M, Krettli A.2002. Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19kD) with clinical immunity to malaria in the Brazilian amazon region. Am J Trop Med Hyg 66:461-466.
17. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder AA, Riley EM. 1996. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 173:765- 769. http://dx.doi.org/10.1093/infdis/173.3.765.
18. Metzger W, Okenu D, Cavanagh D, Robinson J, Bojang K, Weiss H, McBride J, Greenwood B, Conway D. 2003. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol 25:307-312. http://dx.doi.org/10.1046/j.1365-3024.2003.00636.x.
19. Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, Nabeth P, Trappe J, Longacre S, Mercereau-Puijalon O. 2005. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 191:264-271. http://dx.doi.org/10.1086/426398.
20. Polley S, Conway D, Cavanagh D, McBride J, Lowe B, Williams T, Mwangi T, Marsh K. 2006. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 24:4233-4246. http://dx.doi.org/10.1016/j.vaccine.2005.06.030.
21. Taylor RR, Allen SJ, Greenwood BM, Riley EM. 1998. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria.Am J Trop Med Hyg 58:406-413.
22. Courtin D, Oesterholt M, Huismans H, Kusi K, Milet J, Badaut C, Gaye O, Roeffen W, Remarque EJ, Sauerwein R, Garcia A, Luty AJ. 2009. The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS One 4:e7590. http://dx.doi.org/10.1371/journal.pone.0007590.
23. Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK, Kumar S, Chitnis CE, Narum DL, Michon P, Siba PM, Cowman AF, Mueller I, Beeson JG. 2010. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis 51:e50-e60. http://dx.doi.org/10.1086/656413.
24. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, Gilson PR, Murphy VJ, Anders RF, Mueller I, Beeson JG. 2009. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 77:1165-1174. http://dx.doi.org/10.1128/IAI.01129-08.
25. Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, Lanar DE, Dutta S, Rosenthal PJ, Dorsey G, John CC. 2011. Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis 204:19-26. http://dx.doi.org/10.1093/infdis/jir223.
26. Bousema T, Kreuels B, Gosling R. 2011. Adjusting for heterogeneity of malaria transmission in longitudinal studies. J Infect Dis 204:1-3. http://dx.doi.org/10.1093/infdis/jir225.
27. Clark TD, Greenhouse B, Njama-Meya D, Nzarubara B, Maiteki- Sebuguzi C, Staedke SG, Seto E, Kamya MR, Rosenthal PJ, Dorsey G. 2008. Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J Infect Dis 198:393-400. http://dx.doi.org/10.1086/589778.
28. Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J, Vekemans J, Njuguna P, Leach A, Lievens M, Dutta S, von Seidlein L, Savarese B, Villafana T, Lemnge MM, Cohen J, Marsh K, Corran PH, Angov E, Riley EM, Drakeley CJ. 2011. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis 204:9-18. http://dx.doi.org/10.1093/infdis/jir222.
29. Cattani JA, Moir JS, Gibson FD, Ginny M, Paino J, Davidson W, Alpers MP. 1986. Small-area variations in the epidemiology of malaria in Madang Province. P N G Med J 29:11-17.
30. Hii JL, Smith T, Mai A, Mellor S, Lewis D, Alexander N, Alpers MP. 1997. Spatial and temporal variation in abundance of Anopheles (Diptera: Culicidae) in a malaria endemic area in Papua New Guinea. J Med Entomol 34:193-205.
31. Kreuels B, Kobbe R, Adjei S, Kreuzberg C, von Reden C, Bater K, KlugS, Busch W, Adjei O, May J. 2008. Spatial variation of malaria incidence in young children from a geographically homogeneous area with high endemicity. J Infect Dis 197:85-93. http://dx.doi.org/10.1086/524066.
32. Mueller I, Schoepflin S, Smith TA, Benton KL, Bretscher MT, Lin E, Kiniboro B, Zimmerman PA, Speed TP, Siba P, Felger I. 2012. Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A 109:10030-10035. http://dx.doi.org/10.1073/pnas.1200841109.
33. Cook J, Kleinschmidt I, Schwabe C, Nseng G, Bousema T, Corran PH, Riley EM, Drakeley CJ. 2011. Serological markers suggest heterogeneity of effectiveness of malaria control interventions on bioko island, equatorial Guinea. PLoS One 6:e25137. http://dx.doi.org/10.1371/journal.pone.0025137.
34. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SL, Carneiro I, Malima R, Lusingu J, Manjurano A, Nkya WM, Lemnge MM, Cox J, Reyburn H, Riley EM. 2005. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A 102:5108-5113. http://dx.doi.org/10.1073/pnas.0408725102.
35. Noor AM, Mohamed MB, Mugyenyi CK, Osman MA, Guessod HH, Kabaria CW, Ahmed IA, Nyonda M, Cook J, Drakeley CJ, Mackinnon MJ, Snow RW. 2011. Establishing the extent of malaria transmission and challenges facing pre-elimination in the Republic of Djibouti. BMC Infect Dis 11:121. http://dx.doi.org/10.1186/1471-2334-11-121.
36. Stewart L, Gosling R, Griffin J, Gesase S, Campo J, Hashim R, Masika P, Mosha J, Bousema T, Shekalaghe S, Cook J, Corran P, Ghani A, Riley EM, Drakeley C. 2009. Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS One 4:e6083. http://dx.doi.org/10.1371/journal.pone.0006083.
37. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, Cross N, Langer C, Takeo S, Uboldi AD, Thompson JK, Gilson PR, Coppel RL, Siba PM, King CL, Torii M, Chitnis CE, Narum DL, Mueller I, Crabb BS, Cowman AF, Tsuboi T, Beeson JG. 2013. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 191:795-809. http://dx.doi.org/10.4049/jimmunol.1300778.
38. Elliott SR, Fowkes FJ, Richards JS, Reiling L, Drew DR, Beeson JG. 2014. Research priorities for the development and implementation of serological tools for malaria surveillance. F1000Prime Rep 6:100. http://dx.doi.org/10.12703/P6-100.
39. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumea A, Schoepflin S, Stanisic D, Betuela I, Siba P, Felger I, Schofield L, Zimmerman P, Mueller I. 2010. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One 5:e9047. http://dx.doi.org/10.1371/journal.pone.0009047.
40. McNamara D, Thomson J, Kasehagen L, Zimmerman P. 2004. Development of multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Microbiol 42:2403-2410. http://dx.doi.org/10.1128/JCM.42.6.2403-2410.2004.
41. Michon P, Cole-Tobian J, Dabod E, Schoepflin S, Igu J, Susapu M, Tarongka N, Zimmerman P, Reeder J, Beeson J, Schofield L, King C, Mueller I. 2007. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg 76:997-1008.
42. Dutta S, Lalitha P, Ware L, Barbosa A, Moch J, Vassell M, Fileta B, Kitov S, Kolodny N, Heppner D, Haynes J, Lanar D. 2002. Purification, characterization and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 70:3101-3110. http://dx.doi.org/10.1128/IAI.70.6.3101-3110.2002.
43. Hodder A, Crewther P, Anders R. 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69:3286- 3294. http://dx.doi.org/10.1128/IAI.69.5.3286-3294.2001.
44. Mugyenyi CK, Elliott SR, McCallum FJ, Anders RF, Marsh K, Beeson JG. 2013. Antibodies to polymorphic invasion-inhibitory and noninhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria. PLoS One 8:e68304. http://dx.doi.org/10.1371/journal.pone.0068304.
45. Coley AM, Parisi K, Masciantonio R, Hoeck J, Casey JL, Murphy VJ, Harris KS, Batchelor AH, Anders RF, Foley M. 2006. The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1determines binding of an invasion-inhibitory antibody. Infect Immun 74:2628-2636. http://dx.doi.org/10.1128/IAI.74.5.2628-2636.2006.
46. Falk N, Maire N, Sama W, Owusu-Agyei S, Smith T, Beck HP, Felger I. 2006. Comparison of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. Am J Trop Med Hyg 74:944-950.
47. Schoepflin S, Valsangiacomo F, Lin E, Kiniboro B, Mueller I, Felger I. 2009. Comparison of Plasmodium falciparum allelic frequency distribution in different endemic settings by high-resolution genotyping. Malar J 8:250. http://dx.doi.org/10.1186/1475-2875-8-250.
48. Covell G. 1950. Congenital malaria. Trop Dis Bull 47:1147-1167.
49. Reiling L, Richards JS, Fowkes FJ, Barry AE, Triglia T, Chokejindachai W, Michon P, Tavul L, Siba PM, Cowman AF, Mueller I, Beeson JG. 2010. Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. J Immunol 185:6157-6167. http://dx.doi.org/10.4049/jimmunol.1001555.
50. Tongren J, Drakeley C, McDonald S, Reyburn H, Manjurano A, Nkya W, Lemnge M, Gowda C, Todd J, Corran P, RIley E. 2006. Target antigen, age and duration of antigen exposure independently regulate immunoglobulinGsubclass switching in malaria. Infect Immun 74:257-264. http://dx.doi.org/10.1128/IAI.74.1.257-264.2006.
51. Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM. 1995. Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun 63:4382-4388.
52. Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA, Kaslow DC, Riley EM. 1995. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun 63: 456-466.
53. Persson KE, Fowkes FJ, McCallum FJ, Gicheru N, Reiling L, Richards JS, Wilson DW, Lopaticki S, Cowman AF, Marsh K, Beeson JG. 2013. Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity. J Immunol 191:785-794. http://dx.doi.org/10.4049/jimmunol.1300444.
54. McCarra MB, Ayodo G, Sumba PO, Kazura JW, Moormann AM, Narum DL, John CC. 1 December 2011, posting date. Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria. Pediatr Infect Dis J http://dx.doi.org/10.1097/INF.0b013e31822d1451.
55. Duncan CJ, Hill AV, Ellis RD. 2012. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother 8:706-714. http://dx.doi.org/10.4161/hv.19712.
56. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, Sumba PO, Beeson JG, Angov E, Moormann AM, Kazura JW. 2008. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One 3:e3557. http://dx.doi.org/10.1371/journal.pone.0003557.
57. Murungi LM, Kamuyu G, Lowe B, Bejon P, Theisen M, Kinyanjui SM, Marsh K, Osier FH. 2013. A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine 31:3936-3942. http://dx.doi.org/10.1016/j.vaccine.2013.06.042.
58. John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL, Lanar DE, Schluchter MD, Kazura JW. 2005. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg 73: 222-228.
59. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, Lowe B, Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE, Mackinnon MJ, Conway DJ, Marsh K. 2008. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 76:2240-2248. http://dx.doi.org/10.1128/IAI.01585-07.
60. Fowkes FJ, McGready R, Cross NJ, Hommel M, Simpson JA, Elliott SR, Richards JS, Lackovic K, Viladpai-Nguen J, Narum D, Tsuboi T, Anders RF, Nosten F, Beeson JG. 2012. New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis 206:1612-1621. http://dx.doi.org/10.1093/infdis/jis566.
61. Cavanagh D, Dobaño C, Elhassan IM, Marsh K, Elhassan A, Hviid L, Khalil EA, Theander TG, Arnot DE, McBride JS. 2001. Differentialpatterns of human immunogloblin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun 69:1207-1211. http://dx.doi.org/10.1128/IAI.69.2.1207-1211.2001.
62. Kitua AY, Urassa H, Wechsler M, Smith T, Vounatsou P, Weiss NA, Alonso PL, Tanner M. 1999. Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: relationships with clinical malaria and with entomological inoculation rates. Parasite Immunol 21:307-317. http://dx.doi.org/10.1046/j.1365-3024.1999.00230.x.
63. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma E, Tiono A, Konate A, Chilengi R, Theisen M, Dodoo D, Remarque E, Bosomprah S, Milligan P, Sirima S. 2008. Humoral responses to Plasmodium falciparumblood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun 76:759-766. http://dx.doi.org/10.1128/IAI.01147-07.
64. Scopel K, Fontes C, Ferreira M, Braga E. 2006. Factors associated with immunoglobulin G subclass polarization in naturally acquired antibodies in Plasmodium falciparum merozoite surface proteins: a cross-sectional survey in Brazilian Amazonia. Clin Vaccine Immunol 13:810-813. http://dx.doi.org/10.1128/CVI.00095-06.
65. Shi YP, Sayed U, Qari SH, Roberts JM, Udhayakumar V, Oloo AJ, Hawley WA, Kaslow DC, Nahlen BL, Lal AA. 1996. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun 64:2716-2723.